Oligometastatic non-small-cell lung cancer: current treatment strategies
Patrick J Richard, Ramesh Rengan Department of Radiation Oncology, University of Washington, Seattle, WA, USA Abstract: The oligometastatic disease theory was initially described in 1995 by Hellman and Weichselbaum. Since then, much work has been performed to investigate its existence in ma...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2016-11-01
|
Series: | Lung Cancer : Targets and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/oligometastatic-non-small-cell-lung-cancer-current-treatment-strategie-peer-reviewed-article-LCTT |
id |
doaj-12604e078d974966b21aec69246fa09b |
---|---|
record_format |
Article |
spelling |
doaj-12604e078d974966b21aec69246fa09b2020-11-24T23:15:40ZengDove Medical PressLung Cancer : Targets and Therapy1179-27282016-11-01Volume 712914029824Oligometastatic non-small-cell lung cancer: current treatment strategiesRichard PJRengan RPatrick J Richard, Ramesh Rengan Department of Radiation Oncology, University of Washington, Seattle, WA, USA Abstract: The oligometastatic disease theory was initially described in 1995 by Hellman and Weichselbaum. Since then, much work has been performed to investigate its existence in many solid tumors. This has led to subclassifications of stage IV cancer, which could redefine our treatment approaches and the therapeutic outcomes for this historically “incurable” entity. With a high incidence of stage IV disease, non-small-cell lung cancer (NSCLC) remains a difficult cancer to treat and cure. Recent work has proven the existence of an oligometastatic state in NSCLC in terms of properly selecting patients who may benefit from aggressive therapy and experience long-term overall survival. This review discusses the current treatment approaches used in oligometastatic NSCLC and provides the evidence and rationale for each approach. The prognostic factors of many trials are discussed, which can be used to properly select patients for aggressive treatment regimens. Future advances in both molecular profiling of NSCLC to find targetable mutations and investigating patient selection may increase the number of patients diagnosed with oligometastatic NSCLC. As this disease entity increases, it is of utmost importance for oncologists treating NSCLC to be aware of the current treatment strategies that exist and the potential advantages/disadvantages of each. Keywords: oligometastatic, non-small-cell lung cancer, oligoprogressive, treatmenthttps://www.dovepress.com/oligometastatic-non-small-cell-lung-cancer-current-treatment-strategie-peer-reviewed-article-LCTToligometastaticnon-small celllungcanceroligoprogressivetreatment |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Richard PJ Rengan R |
spellingShingle |
Richard PJ Rengan R Oligometastatic non-small-cell lung cancer: current treatment strategies Lung Cancer : Targets and Therapy oligometastatic non-small cell lung cancer oligoprogressive treatment |
author_facet |
Richard PJ Rengan R |
author_sort |
Richard PJ |
title |
Oligometastatic non-small-cell lung cancer: current treatment strategies |
title_short |
Oligometastatic non-small-cell lung cancer: current treatment strategies |
title_full |
Oligometastatic non-small-cell lung cancer: current treatment strategies |
title_fullStr |
Oligometastatic non-small-cell lung cancer: current treatment strategies |
title_full_unstemmed |
Oligometastatic non-small-cell lung cancer: current treatment strategies |
title_sort |
oligometastatic non-small-cell lung cancer: current treatment strategies |
publisher |
Dove Medical Press |
series |
Lung Cancer : Targets and Therapy |
issn |
1179-2728 |
publishDate |
2016-11-01 |
description |
Patrick J Richard, Ramesh Rengan Department of Radiation Oncology, University of Washington, Seattle, WA, USA Abstract: The oligometastatic disease theory was initially described in 1995 by Hellman and Weichselbaum. Since then, much work has been performed to investigate its existence in many solid tumors. This has led to subclassifications of stage IV cancer, which could redefine our treatment approaches and the therapeutic outcomes for this historically “incurable” entity. With a high incidence of stage IV disease, non-small-cell lung cancer (NSCLC) remains a difficult cancer to treat and cure. Recent work has proven the existence of an oligometastatic state in NSCLC in terms of properly selecting patients who may benefit from aggressive therapy and experience long-term overall survival. This review discusses the current treatment approaches used in oligometastatic NSCLC and provides the evidence and rationale for each approach. The prognostic factors of many trials are discussed, which can be used to properly select patients for aggressive treatment regimens. Future advances in both molecular profiling of NSCLC to find targetable mutations and investigating patient selection may increase the number of patients diagnosed with oligometastatic NSCLC. As this disease entity increases, it is of utmost importance for oncologists treating NSCLC to be aware of the current treatment strategies that exist and the potential advantages/disadvantages of each. Keywords: oligometastatic, non-small-cell lung cancer, oligoprogressive, treatment |
topic |
oligometastatic non-small cell lung cancer oligoprogressive treatment |
url |
https://www.dovepress.com/oligometastatic-non-small-cell-lung-cancer-current-treatment-strategie-peer-reviewed-article-LCTT |
work_keys_str_mv |
AT richardpj oligometastaticnonsmallcelllungcancercurrenttreatmentstrategies AT renganr oligometastaticnonsmallcelllungcancercurrenttreatmentstrategies |
_version_ |
1725589733927550976 |